User:Etherese/sandbox
Matt Gline is the Chief Executive Officer of Roivant, an American biotechnology company. Gline joined Roivant in 2016 and served as Chief Financial Officer from 2017 until 2021 when he was appointed Chief Executive Officer. [1]
Prior to Roivant, Gline was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Gline earned his AB in Physics from Harvard College.[2]
Gline was motivated by his love for complex problems and entrepreneurship to seek out roles in finance and biotechnology. Gline is credited with leading Roivant to several successful financing rounds.
Early life and education
[edit]Gline grew up in South Orange, New Jersey. His father was a bankruptcy lawyer, and his mother taught at a Jewish pre-school. Gline grew up Jewish.
Career
[edit]Gline earned his bachelor’s degree in physics from Harvard University in 2006, where he met his now wife, Laura Jean Ridge, a professor at The University of Cincinnati, a nurse practitioner, and the founder of Nursing for All – a nonprofit that supports nurse-led public health initiatives in Liberia.
He lives in New York City with his wife, their son and their rescue dog Josie.
After graduating from Harvard, Gline worked at a number of financial firms including Goldman Sachs, Lehman Brothers, and Barclays Capital Inc. In 2012, he caught the entrepreneurial bug and founded Fourthree, a risk analytics technology and consulting company. Two years later, Gline took on the role of Vice President of Fixed Income Digital Structuring at Goldman Sachs.
In March 2016, Gline joined Roivant Sciences in its early stages and served as Chief Financial Officer where he led the company to several successful financing rounds, including the $3b strategic alliance with Sumitomo Dainippon Pharma in 2019. [1] He was promoted to Chief Executive Officer in January 2021, succeeding Vivek Ramaswamy, the founder. Roivant went public via a SPAC in October 2021. [3]
Board service and memberships
[edit]Gline serves on the Board of Advisors of Life Science Cares New York[4], whose mission is to activate financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities.
References
[edit]- ^ a b "Vivek Ramaswamy and Matt Gline pen shareholder letters about the changes now underway at Roivant". Endpoints News. Retrieved 2023-04-27.
- ^ "Matthew Gline". Milken Institute. Retrieved 2023-04-27.
- ^ Inc, Roivant Sciences (2021-10-01). "Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing". GlobeNewswire News Room. Retrieved 2023-04-27.
{{cite web}}:|last=has generic name (help) - ^ "Board of Advisors - New York". Life Science Cares. Retrieved 2023-04-27.